The estimated Net Worth of Kamran Alam is at least 7.71 百万$ dollars as of 24 August 2023. Mr. Alam owns over 33,000 units of Rocket Pharmaceuticals Inc stock worth over 4,910,539$ and over the last 5 years he sold RCKT stock worth over 751,565$. In addition, he makes 2,051,460$ as Senior Vice President - Finance、 Principal Financial Officer at Rocket Pharmaceuticals Inc.
Kamran has made over 4 trades of the Rocket Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 33,000 units of RCKT stock worth 76,890$ on 24 August 2023.
The largest trade he's ever made was selling 33,000 units of Rocket Pharmaceuticals Inc stock on 24 August 2023 worth over 76,890$. On average, Kamran trades about 6,533 units every 49 days since 2019. As of 24 August 2023 he still owns at least 258,042 units of Rocket Pharmaceuticals Inc stock.
You can see the complete history of Mr. Alam stock trades at the bottom of the page.
Kamran Alam CPA serves as Senior Vice President - Finance, Principal Financial Officer of the Company. Prior to joining Rocket, Mr. Alam was Vice President, Finance at AveXis, Inc. from April 2016 to October 2019. From March 2013 to April 2016, he held positions of increasing responsibility at Aptinyx, where at the time of his departure he was a Senior Director, Finance and Accounting. Previously, he was a Director of Finance at Naurex, and earlier in his career, Mr. Alam held various finance and project management roles with increasing responsibility at Ovation Pharmaceuticals, Lundbeck and Fresenius Kabi. Mr. Alam is a Certified Public Accountant, and received his Bachelor of Business Administration degree from the Ross School of Business at University of Michigan and an M.B.A. in Finance from the Kelley School of Business at Indiana University.
As the Senior Vice President - Finance、 Principal Financial Officer of Rocket Pharmaceuticals Inc, the total compensation of Kamran Alam at Rocket Pharmaceuticals Inc is 2,051,460$. There are 2 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of 3,883,650$.
Kamran Alam is 41, he's been the Senior Vice President - Finance、 Principal Financial Officer of Rocket Pharmaceuticals Inc since 2019. There are 16 older and no younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.
Kamran's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, STE 1430, DALLAS, TX, 75247.
Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over 45,364,690$ worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth 48,979,646$ . The most active insiders traders include Investments, Lpwong Roderic...、Mikael Dolsten、Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of 1,269,815$. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth 19,684$.
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: